Kanwaldeep Kaur Mallhi, MD

Kanwaldeep Kaur Mallhi, MD

Hematology-Oncology

On staff since October 2016

  • Dr. Kanwaldeep Mallhi is a pediatric oncologist and hematologist who specializes in nonmalignant blood disorders in children. These disorders include immunodeficiencies, bone marrow failure and metabolic errors. She is an expert in pediatric blood stem cell transplants, and her research focuses on alternative donor sources and the development of reduced-intensity conditioning regimens, which use radiation, chemotherapy or other procedures to remove diseased or failing cells prior to transplant. 

     

     

     

     

     

Overview

Board Certification(s)

Pediatrics
Pediatric Hematology-Oncology

Medical/Professional School

Rosalind Franklin University of Medicine and Science - Chicago Medical School, North Chicago

Residency

SUNY - University of Buffalo, Buffalo

Fellowship

University of British Columbia Post Graduate Medical Education, Vancouver
University of Minnesota Masonic Children's Hospital Pediatric Fellowship, Minneapolis

Clinical Interests

Active Clinical Trials:

Study Number 2032: Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

Study Number 9818:  Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

Study Number 9867:  Haploidentical Bone Marrow Transplantation in Sickle Cell Patients

 

Research Description

 

My research is focused on develop local and national expertise in HCT for non-malignant disorders. Specific areas of interest include inborn errors of metabolism disorders and bone marrow failure syndromes, utilizing reduced intensity conditioning regimens, alternative donors and gene editing.